Positive Outlook for Moderna Driven by Vaccine Distribution and Oncology Pipeline

UBS analyst Eliana Merle maintained a Buy rating on Moderna today and set a price target of $70.00.

Eliana Merle’s rating is based on several key considerations. The recent ACIP recommendation, which aligns with FDA approvals, is seen as a positive development for Moderna. This recommendation could facilitate broader access to COVID vaccines at pharmacies, potentially boosting vaccine distribution and sales. Despite uncertainties in the US market, Moderna’s pipeline, particularly in oncology, is viewed as undervalued, with upcoming Phase 3 melanoma data in 2026 expected to be a significant growth driver.
Additionally, Moderna’s international prospects are promising, with anticipated respiratory vaccine supply agreements with the UK, Canada, and Australia projected to generate nearly $1 billion annually starting in 2026. The company’s revenue guidance for 2025, which includes substantial contributions from both US and ex-US markets, further supports the Buy rating. These factors collectively suggest a favorable outlook for Moderna’s stock, justifying Eliana Merle’s positive assessment.

According to TipRanks, Merle is an analyst with an average return of -3.4% and a 42.63% success rate. Merle covers the Healthcare sector, focusing on stocks such as Moderna, PTC Therapeutics, and Ascendis Pharma.